Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)

Chronic Sinusitis Clinical Trial

Official title:

Phase 2 Trial to Evaluate Safety & Efficacy of Topical Nitric Oxide Releasing Sinus Irrigation (NOSi) as Compared to Budesonide-Saline (Control) in the Management of Biofilm-Associated Recalcitrant Chronic Rhinosinusitis (RCRS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04163978
• Other study ID #: NOSi-CTP-02
• Status: Completed
• Phase: Phase 2
• Start date: October 27, 2019
• Est. completion date: May 3, 2022

Study information

• Verified date: April 2022
• Source: Sanotize Research and Development corp.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This a single center, randomized controlled trial to evaluate safety & efficacy of topical nitric oxide releasing sinus irrigation (NOSi) as compared to budesonide-Saline (Control) in the management of biofilm-associated recalcitrant chronic rhinosinusitis (RCRS). It is hypothesized that a daily treatment of NOSi over a 6-week period will be safe and effective at reducing clinical symptoms associated with RCRS.

Description:

This is a prospective, single center, Phase 2, double-blinded, randomized, controlled, parallel group trial study. Up to fifty-four (54) participants will be enrolled (based on power analysis based on outcomes from a previous dose-tolerance study. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study and randomized in to the Investigational Medicinal Product (IMP) or Non Investigational Medicinal Product (NIMP) at a 2:1 ratio (NOSi:Budesonide). Each participant will be managed as an outpatient for the 42 days of the study. Participants will be administered NOSi or budesonide in saline by self-administration, at home, as a sinus irrigation to their nasopharynx and sinuses once a day. Participants will be asked to return to the clinic for evaluations on Day 21(±2), Day 43(±2) and Day 63 (±2) following the start of study interventions.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: May 3, 2022
• Est. primary completion date: May 3, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent must be obtained from the participant prior to entering the study.

2. Must be = 19 years of age unless local laws dictate otherwise

3. English speaking

4. Willing and able to return to the study site for protocol required visits.

5. Documented diagnosis of chronic sinusitis with biofilm after a treatment of at least 3 months of a combination of well executed sinus surgery, regular irrigation with topical steroids or a mucosal atomization device and surfactants and at least one course of culture directed oral antibiotics

6. Persistent or worsening symptoms within 30 days of wash-in with budesonide. Specifically, documented by two SNOT-22 scores greater than or equal to 20 indicating stable (within 9 points) or worsening symptoms. SNOT-22 evaluations must be at least 7 days and no more than 30 days apart. Second SNOT-22 must be used as baseline.

7. Participant has been on a stable course of only Pulmicort and saline irrigation for a minimum of 30 days prior to randomization

8. Must be willing to use an adequate and documented form of contraception (or abstinence) from the time of the first dose with the IMP until after the last dose of IMP

Exclusion Criteria:

1. Presence of prior history of sinonasal tumors

2. Isolated sphenoid sinusitis or other sinus cavities that are not accessible to a nasal/sinus rinse as done by the patient in the head forward position

3. Autoimmune diseases affecting the upper airway eg Systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis etc

4. Immuno-compromised patients, and patients with impairment in mucociliary function (e.g., cystic fibrosis, Kartagener syndrome)

5. Severe underlying disease with anticipated survival less than 6 months

6. Females who are pregnant, breastfeeding, or plan to become pregnant during the course of the study up to 1 weeks after the last dose/study visit

7. Has used any investigational drug(s) within 30 days preceding randomization visit (Day 1);

8. Suffers from a condition, which, in the opinion of the medical investigator, would compromise their safety and / or their adherence to the study protocol

9. Systemic antibiotics, corticosteroids or antifungals within 30 days of randomization

10. Intranasal or irrigation with antibiotics, antifungals or antiseptics or any other sinusitis treatment other than Pulmicort within 30 days of randomization

11. Has a family member living in the same household, also enrolled or planning to enroll in this study.

Related Conditions & MeSH terms

• Chronic Sinusitis
• Sinusitis

Intervention

Drug:
• Nitric Oxide
in situ 240mL nitric oxide releasing sinus irrigation solution
• Budesonide
Saline based sinus irrigation 1mg Budesinide solution

Locations

Country	Name	City	State
Canada	St. Paul's Hospital	Vancouver	British Columbia

Sponsors (1)

Lead Sponsor	Collaborator
Sanotize Research and Development corp.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To assess the efficacy of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis (RCRS) as measured by the Sino-Nasal Outcome Test (SNOT-22)	Proportion of participants experiencing a 9-point reduction in Sino-Nasal Outcome test (SNOT-22) score (0-5 scale of 22 parameters with a total maxmimum score of 110 and an increased value representing worsening of condition)	42 days
Primary	To assess the safety of NOSi compared to Budesonide on disease specific quality of life in participants with biofilm-associated recalcitrant chronic rhinosinusitis	Severity and frequency of adverse events as well as clinically significant Changes in laboratory findings, vital signs, histology, olfaction, and methemoglobin levels.	63 days
Secondary	To evaluate the efficacy of NOSi compared to Budesonide on the reduction of Modified Lund-Kennedy Scores (MLK)	Mean change in MLK score as compared to control (Scale of 0-2 for 6 locations on each side (maximum total score 24); increase represents worsening	Days 21, 42, 63
Secondary	To evaluate the efficacy of NOSi compared to Budesonide on quality of life improvements (EQ-5D-5L);	Mean change in EQ-5D-5L index score as compared to control (Scale 0-100; increase indicates worsening)	Days 21, 42, 63
Secondary	To evaluate the efficacy of NOSi compared to Budesonide on the density of pathogens	Mean change in pathogen density compared to control; (log10 cfu/g)	Days 21, 42, 63
Secondary	To evaluate the efficacy of NOSi compared to Budesonide on cilia functionality	Proportion of participants with functional cilia which is known to be denuded by biofilm as determined by the saccharin test compared to control	Days 43 & 63
Secondary	To evaluate the efficacy of NOSi compared to Budesonide on biofilm elimination	Proportion of participants with biofilm elimination compared to control	Days 43 & 63